Use of Aldosterone Antagonists in Resistant Hypertension

Progress in Cardiovascular Diseases

Volumn 48, Issue 6, 2006, Pages 387-396

  Calhoun, David A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALDOSTERONE ANTAGONIST; AMILORIDE; AMPHETAMINE; ANGIOTENSIN RECEPTOR BLOCKER; ANTIHYPERTENSIVE AGENT; BUMETANIDE; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; COCAINE; CYCLOSPORIN; DECONGESTIVE AGENT; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; ERYTHROPOIETIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; METHAMPHETAMINE; METHYLPHENIDATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AGING; AORTA COARCTATION; ARTERIAL PRESSURE; ARTICLE; BLADDER NECK STENOSIS; BLOOD PRESSURE REGULATION; BREAST TENDERNESS; CHRONIC KIDNEY FAILURE; CUSHING DISEASE; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FOLLOW UP; GLYCYRRHIZA; GYNECOMASTIA; HIGH RISK PATIENT; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; LABORATORY TEST; MENSTRUATION DISORDER; PHEOCHROMOCYTOMA; PREDICTION; PREVALENCE; SALT INTAKE; SEXUAL DYSFUNCTION; SLEEP APNEA SYNDROME; SODIUM RETENTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URETER DISEASE;

ALDOSTERONE ANTAGONISTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33646547562     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2006.02.002     Document Type: Article

References (34)

1. Hajjar I., and Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290 (2003) 199-206
2. Wolf-Maier K., Cooper R.S., Banegas J.R., et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289 (2003) 2363-2369
3. Riehle J.F., Lackland D.T., Okonofau E.C., et al. Ethnic differences in the treatment and control of hypertension in patients with diabetes. J. Clin. Hypertens. 7 (2005) 445-454
4. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
5. Cushman W.C., Ford C.E., Cutler J.A., et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. 4 (2002) 393-404
6. Lloyd-Jones D.M., Evans J.C., Larson M.G., et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 36 (2000) 594-599
7. Lloyd-James D.M., Evans J.C., Larson M.G., et al. Treatment and control of hypertension in the community: a prospective analysis. Hypertension 40 (2002) 640-646
8. Bramlage P., Pittrow D., Hans-Ulrich W., et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am. J. Hypertens. 17 (2004) 904-910
9. Nieto F.J., Young T.B., Lind B.K., et al., for the Sleep Heart Health Study. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA 283 (2000) 1829-1836
10. Peppard P.E., Young T., Palta M., et al. Prospective study of the association between sleep-disordered breathing and hypertension. N. Engl. J. Med. 342 (2000) 1378-1384
11. Logan A.G., Perlikowski S.M., Mente A., et al. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J. Hypertens. (2001) 2271-2277
12. Grote L., Hedner J., and Peter J.H. Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension. J. Hypertens. 18 (2000) 679-685
13. Lavie P., and Hoffstein V. Sleep apnea syndrome: a possible contributing factor to resistant hypertension. Sleep 24 (2001) 721-725
14. Becker H.F., Jerrentrup A., Ploch T., et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 107 (2003) 68-73
15. Logan A.G., Tkacova R., Perlikowski S.M., et al. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. Eur. Respir. J. 21 (2003) 241-247
16. Robinson G.V., Stradling J.R., and Davies R.J.O. Obstructive sleep apnoea/hypopnea syndrome and hypertension. Thorax 59 (2004) 1089-1094
17. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 40 (2002) 892-896
18. Gallay B.J., Ahmad S., Xu L., et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am. J. Kidney Dis. 37 (2001) 699-705
19. Eide I.K., Torjesen P.A., Drolsum A., et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J. Hypertens. 22 (2004) 2217-2226
20. Hermida R., Ayala D.E., Calvo C., et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension 46 (2005) 1-7 (pt 2)
21. Vollmer W.M., Sacks F.M., Ard J., et al. Effects of diet and sodium on blood pressure: subgroup analysis of the DASH-sodium trial. Ann. Intern. Med. (2001) 1019-1028
22. Taler S.J., Textor S.C., and Augustine J.E. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 39 (2002) 982-988
23. Garag J.J.P., Elliott W.J., Folker A., et al., for the RUSH Hypertension Service. Resistant hypertension revisited: a comparison of 2 university-based cohorts. Am. J. Hypertens. 18 (2005) 619-626
24. Saseen J.J., Carter B.L., Brown T.E., et al. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension 28 (1996) 109-114
25. Stergiou G.S., Skeva I.I., Baibas N.M., et al. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J. Cardiovasc. Pharmacol. 35 (2000) 937-941
26. Ouzan J., Pérault C., Lincoff A.M., et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am. J. Hypertens. 15 (2002) 333-339
27. Nishizaka M.K., Zaman M.A., and Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. 16 (2003) 925-930
28. Saha C., Eckert G.J., Ambrosius W.T., et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 46 (2005) 481-487
29. Weinberger M.H., Roniker B., Krause S.L., et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 15 (2002) 709-716
30. Flack J.M., Oparil S., Pratt J.H., et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol. 41 (2003) 1148-1155
31. Krum H., Nolly H., Workman D., et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40 (2002) 117-123
32. Prisant L.M., Krum H., and Roniker B. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?. J. Clin. Pharmacol. 43 (2003) 1203-1210
33. Goodfriend T.L., Ball D.L., and Gardner H.W. An oxidized derivative of linoleic acid affects aldosterone secretion by adrenal cells in vitro. Prostaglandins Leukot. Essent. Fat. Acids 67 (2002) 163-167
34. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 125 (2004) 112-117